Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

NCT02913313 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT02913313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02913313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2016
Completion date
January 25, 2024
Enrollment
101 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

broad solid tumor